10x Research: USDT Issuance on Ethereum Surpasses Tron, ETH Could Become Primary Beneficiary of Stablecoin Growth
Svmuu News 10x Research posted on the X platform, stating that ETH has shown lackluster performance over the past five years, trading around the $2,000 level it reached in the previous cycle. Since November, due to subdued on-chain activity limiting ETH demand and value accumulation, 10x Research has maintained a cautious stance. After a 57% decline from its August 2025 high, ETH is currently at a relatively low valuation, while BTC has fallen about 42% over the same period. Despite significant market cap losses, such as ETH treasury companies like Bitmine withdrawing approximately $8 billion, capital accumulation continues. Recently, the issuance of USDT on the Ethereum network has surpassed that on Tron. This has sparked the view that Ethereum could become the primary beneficiary of stablecoin growth and potentially serve as the Wall Street-driven financial backbone for on-chain infrastructure. 10x Research is reassessing whether ETH is approaching an inflection point or if structural resistance persists.
Source:Odaily · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
3
Will the BEAM token go to zero? Could it rise to $1,000? An in-depth analysis of the Beam network and its market prospects
-
4
The analysis points out that Iran’s overlapping centers of power complicate efforts to end the war with the United States, and that the Revolutionary Guards possess significant operational autonomy.
-
5
Israeli West Bank Settler Tells BBC Attacks on Palestinians Are Justified as Revenge, Equating One Jewish Life to "10 Million" Palestinians
-
6
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
7
What Is JGN? Analysis of the JGN (Sword Saint Coin) Project’s Positioning, Features, and Value
-
8
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
9
Analysis Compares Healthcare ETFs: Invesco Nasdaq Biotech ETF (IBBQ) Saw 45.5% One-Year Return, Outperforming State Street Healthcare Select Sector SPDR ETF (XLV)
-
10
Analysis: Vanguard Small-Cap Growth ETF (VBK) up 21% YTD 2026, Outperforming Large-Cap Growth ETF (VONG) at 0.3% YTD
Markets Today
Recommended Reading






